CEO SUMMARY: Probably the most challenging infections for hospitals to control and reduce are methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). The laboratory at one New York hospital introduced algorithms to screen for the presence of each infection. In the past five years, the hospital not only cut costs by almost $3 million
Tag: pcr testing
CEO SUMMARY: Motivated by the goal of delivering more value to clinicians and client hospitals, the lab team at TriCore Reference Laboratories in Albuquerque, New Mexico, is proactively introducing new services. One such initiative is to travel to hospitals to participate in rounds and consult with physicians regularly. Another initiative improved the accuracy of C.
IT WAS 1979 WHEN VICTOR KIAM jump-started sales of Remington electric razors with his classic, witty ad campaign, “I liked the product so much, I bought the company!” Now the same thing is happening with a benchtop-sized automated system for molecular PCR testing.
In this case, it is Becton Dickenson and Company (BD) which liked HandyLab,
CEO SUMMARY: Viracor Laboratories is preparing to handle expanded volumes of influenza testing prior to the start of the next flu season. It will use added instrumentation and expanded working hours to expand capacity. Another strategy is to use influenza A testing as a way to reduce the overall number of influenza specimens that might
CEO SUMMARY: One of the hottest market segments in in vitro diagnostics (IVD) is rapid testing. However, because labs now often have multiple choices when selecting a rapid test, IVD manufacturers recognize the need to differentiate their products by adding additional features and benefits. In the case of 3M’s new rapid test for influenza, the
CEO SUMMARY: With the clinical laboratory industry now enjoying growing interest by professional investors, THE DARK REPORT traveled to New York City to meet with financial analyst William B. Bonello, of U S Bancorp Piper Jaffray. Bonello co-authored a just-released overview of what he calls the “diagnostic services industry.” He is bullish on the future
DECEMBER 7, 1999 WAS NOT an auspicious day for Hoffmann-LaRoche. One of its patents related to the PCR testing process was ruled invalid by a Federal District Court.
The ruling involved Roche’s ’818 Taq patent, an enzyme used in the PCR process. The Court found that the patent holder had intentionally withheld material information and distorted
CEO SUMMARY: Expect a battle royale for hospital reference and esoteric testing by the handful of labs that offer such testing to hospitals throughout the country. With the merger of Quest Diagnostics Incorporated and SmithKline Beecham Clinical Laboratories now a fact, competitors are already swarming into hospital labs with offers of better service and improved
CEO SUMMARY: Pick your trend: declining reimbursement, consolidation, clinical integration, downsizing, and capitated reimbursement. These trends all continued to shape the way laboratories organized to provide services. But 1997’s wildcard was the federal government. Between investigations and new regulations, laboratories were hit hard.
FOR THE clinical laboratory industry, 1997’s biggest surprise was both unexpected and unpleasant:
CEO SUMMARY: During the years of sustained bad financial news that dogged the major laboratories, there was a reluctance to speak publicly about any aspect of the laboratory business. That era seems to be ending, as LabCorp and the other national laboratories become friendlier and more accessible. A trip to LabCorp’s headquarters in Burlington, North